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Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients
with Parkinson’s disease (PD).
Materials and methods: We had telephone calls with 54 patients from 11 neurology centers who were on LCIG treatment, and 44
patients or their caregivers were included in an eight-item survey between September 2015 and June 2016. The reliability and validity of
the survey were evaluated with intraclass correlation coefficients for every question separately.
Results: Average age of the patients were 63.48 and the duration of PD was 12.79 years. Average LCIG treatment period was 15.63
months. Percentages of the patients who reported they were ‘better’ after LCIG treatment were as follows: 80% for time spent off, 55% for
dyskinesia, 65% for tremor, 85% for gait disorder, 50% for pain, 50% for sleep disorders, 42.5% for depression, 32.5% for incontinence,
and 70% for activities of daily living. Cronbach’s alpha was 0.795 and the intraclass correlation coefficient was reliable for the items.
Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG
treatment in many aspects of the disease.
Key words: Parkinson’s disease, levodopa carbidopa intestinal gel, efficacy

1. Introduction
Parkinson’s disease (PD) is the second most common
progressive neurodegenerative disease occurring
as a result of the dopaminergic neuron loss in the
nigrostriatal pathway [1]. There can be motor as well as
nonmotor symptoms in PD. As the disease progresses,
the patients begin to need device-aided treatments such
as apomorphine pump, deep brain stimulation (DBS),
and levodopa/carbidopa intestinal gel (LCIG). Thanks to
these treatments, both motor and nonmotor symptoms of
the patients are significantly treated and activities of daily
living (AoDL) become more comfortable [2].

Dopamine replacement with its oral precursor
levodopa (L-DOPA) to stimulate striatal dopamine
receptors is the gold-standard treatment of PD [3].
However, the therapeutic window of levodopa narrows
progressively within years and most patients develop
motor complications eventually, such as motor fluctuations
and dyskinesia [4]. Due to its short plasma half-life,
oral levodopa treatment cannot stimulate receptors in
a continuous manner and causes oscillations of plasma
levels, which are closely correlated with motor fluctuations
[5]. In this period of PD, patients may need device-aided
treatments. LCIG is a suspension administered to the
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jejunum directly via percutaneous gastrojejunostomy tube
to achieve more stabilized plasma levodopa levels. Based
on multiple studies LCIG is effective in eliminating motor
and nonmotor fluctuations and improving quality of life in
advanced stages of PD [6–8].
In this study, we aimed to evaluate the efficacy of LCIG
treatment for PD on motor and nonmotor symptoms and
AoDL via a structured survey as a multicenter study.
2. Materials and methods
The Turkish Duodopa study was a cross-sectional,
descriptive study designed to evaluate the efficacy of
continuous LCIG infusion via a previously prepared survey
to compare former and subsequent treatment of motor and
nonmotor symptoms. This study was conducted between
September 2015 and September 2016. Eleven neurology
centers across Turkey were included in the study. The survey
comprises a total of 9 questions. Four questions are related
to motor symptoms (time spent off, dyskinesia, tremor, gait
disorder), 4 questions are related to nonmotor symptoms
(pain, sleep disorders, depression, incontinence), and one
is related to AoDL. Questions in the survey are given in
Appendix 1. Patients’ demographics, PD onset, and LCIG
treatment duration were collected prospectively.
Fifty-four patients who were receiving LCIG were
evaluated for this study. We could not enroll 10 patients
because of missing contact information (n = 6), unwillingness
to participate in the survey (n = 1), termination of therapy
at the time of contact for loss of appetite (n = 2), and
inadequate treatment response (n = 1). A total of 44 patients
were evaluated. The patients and their caregivers were then
asked to answer the survey on the telephone. Patients and
their caregivers were asked to scale the effect of LCIG on
every symptom, comparing the periods before and after
the treatment as ‘better’, ‘same’, ‘worse’, ‘don’t know’, or ‘did
not have this symptom’. Results were expressed as absolute
numbers and frequencies. All interviews were recorded
and two neurology residents listened to and evaluated
these interviews separately. The protocol of the study was
approved by the Ethics Committee of Ankara University.
2.1. Statistics
To compare the variables before and after LCIG initiation,
the Wilcoxon matched pairs signed-rank test was used.
The survey’s reliability and validity were assessed with
Cronbach’s alpha and intraclass correlation coefficients
(ICCs; interrater reliability) (Table 1). The statistical
significance level was 0.05. SPSS 23.0 for Mac (IBM Corp.,
Armonk, NY, USA) was employed for data processing and
analysis.
3. Results
We collected the patient data from 11 centers across Turkey
specialized on movement disorders, and we tried to reach

all the patients who were receiving LCIG treatment on the
telephone. Twenty-two of 44 patients (50%) were female.
The mean of the age of patients, duration of PD, and
LCIG treatment duration were 63.48 ± 8.4 years, 12.79
± 9.1 years, and 15.63 ± 9.46 months, respectively. The
demographic data of patients are shown in Table 2.
The percentages of patients who reported ‘better’ motor
symptoms for time spent off, dyskinesia, tremor, and gait
disorder were 80%, 55%, 65%, and 85%, respectively.
The percentages of nonmotor symptoms (pain, sleeping
disorders, depression, and incontinence) that improved
were 50%, 50%, 42.5%, and 32.5%, respectively. The details
of the answers given by the patients are presented in the
Figure.
According to the patients and their caregivers’ surveys
on the telephone, 70% of all patients reported that they
had improved in terms of AoDL after LCIG treatment.
Motor symptoms responded significantly better than
nonmotor symptoms. All of the parameters investigated
except incontinence were rated as significantly better.
Cronbach’s alpha for the survey was 0.795. The
reliability and validity were evaluated with the ICC for
every question separately (Table 1) between raters.

Table 1. Intraclass correlation coefficient (ICC).
Item

ICC

Motor Time spent ‘off ’

0.981

Dyskinesia

0.946

Tremor

0.995

Gait disorder

0.792

Nonmotor pain

0.980

Sleep disorders

1.000

Depression

0.958

Incontinence

0.991

Activities of daily living

0.995

Table 2. Characteristics of the patients with Parkinson’s disease.
Parameter

Value

N

44

Age (years), mean (SD)
Sex, n (%)

63.48 (8.4)
Male

22 (50)

PD duration (years), mean (SD)

12.79 (9.1)

LCIG duration (months), mean (SD)

15.63 (9.46)

PD: Parkinson’s disease, LCIG: Levodopa carbidopa intestinal gel.
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Figure. Answers given by patients to questions in the survey.

The values for Cronbach’s alpha and ICCs gave rise to
the thought that the telephone questionnaire can be used
as a valid and reliable tool.
4. Discussion
In this study, we have conducted a quite simple survey
to investigate the effect of LCIG on frequent motor and
nonmotor symptoms of PD. The present study is the first
study of LCIG treatment for PD patients in Turkey, with
positive effects of the procedure on motor and nonmotor
symptoms and AoDL.
Although there are numerous studies showing that
LCIG is effective in treating PD [9–12], there is only one
randomized, controlled, double-blind, double-dummy
study to prove its efficacy [13]. Different types of scales
(Unified PD Rating Scale: UPDRS, Parkinson Patient
Quality of Life: PDQ, Nonmotor Symptoms Scale: NMSS,
etc.) were employed in these studies to measure the efficacy
of LCIG [14,15].
The improvement of motor symptoms was higher
than nonmotor symptoms in our series. While the highest
motor symptom recovery was for gait disorder (85%),
highest nonmotor symptom recovery was for sleep (50%).
The recovery of AoDL was found to be 50%. Some studies
have also shown similar positive results [11,14]. It was
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demonstrated by Chang et al. that the decrease of ‘off ’ time
was 67% and 73% in comparison to baseline at the 6th and
12th months, respectively [6]. Fernandez et al. reported
improvement of dyskinesia and at the same time increased
‘on’ time without troublesome dyskinesia at a rate of 62.9%,
while the decrease of ‘on’ time with troublesome dyskinesia
was 22.5% [7]. It was found by Buongiorno et al. that the
efficacy of LCIG on gait disorders like falls and freezing
of gait decreased the rate of such symptoms from 97% to
65% [8]. With regard to motor symptoms, the findings of
the current study are compatible with the previous studies.
Băjenaru et al. evaluated 113 patients in their
retrospective study conducted in nine centers located
in Romania. With LCIG treatment, the ‘on’ period of
the patients (period of improved mobility known as ‘on’
period) increased to 6.14 h on average, and dyskinesia
periods decreased 29.4%. It was shown that the nonmotor
symptoms and life quality scores of the patients
improved dramatically [16]. In the study carried out by
Cáceres-Redondo et al., 29 PD patients receiving LCIG
treatment were monitored for two years. While similar
improvements in motor and nonmotor symptoms of
the patients were detected, it was revealed that although
cognitive performance of the patients regressed, long-term
well-being continued [17]. According to a large review
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Table 3. Efficacy of levodopa carbidopa intestinal gel on motor and nonmotor symptoms.
Authors

Year

‘Off ’ time

‘On’ time with
dyskinesia

UPDRS II

UPDRS III

NMSST,
% improvement

Honig et al. [11]

2009

-

-

11.6 ± 7.2

4.5 ± 2.2

56

Cáceres-Redondo et al. [17]

2014

32.2 mo, 24.6 ± 7.2

-

16.5 ± 5.0

29.5 ± 6.4

17

Antonini et al. [19]

2015

–4.7 ± 3.4

–1.7 ± 5.0

–3.1 ± 8.7

–3.3 ± 11.0

29

Sensi et al. [20]

2014

24 mo, 1.0 ± 0.6

-

-

24 mo, 34.7 ± 12.4

27

Bohlega et al. [21]

2015

6 mo, 1.4

-

-

19.6 ± 8.4

65

NMSST: Nonmotor Symptom Scale Total score, mo: months, UPDRS: Unified Parkinson’s Disease Rating Scale

published recently, the evidence about the effect of LCIG on
motor fluctuations and quality of life is of average quality,
and the evidence about the effect of LCIG on nonmotor
symptoms is of dramatically low quality (65%–14%) [18].
The effects of LCIG on motor and nonmotor symptoms of
PD are shown in Table 3 [19–21].
There are a few limitations of our study, including a
relatively small number of patients, retrieval of information
through telephone calls, and a lack of information about
side effects and complications.
In conclusion, we assume that the eight items of the
survey developed to assess patient response to LCIG could

be used as a telephone follow-up tool, especially with
patients who have difficulty reaching a hospital.
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Appendix 1. Survey form used in the study.
Evaluation of Motor and Nonmotor Symptoms
Motor symptoms
Is there a change when she/he is unconscious (bad)?
Is there a change in her/his reflexes (saltatory, convulsion,
spasms - not shivering) during the day?
Is there a change in shivering?
Is there a change her/his difficulty in walking and imbalance?
Nonmotor symptoms
Is there a change in aches?
Is there a change in insomnia?
Is there a change in senses of unhappiness, sadness, moodiness?
Is there a change in urinary incontinence problem?
Daily life activities
Is there a change in her/his daily chores (eating, dressing,
showering, etc.)?
TOTAL

72

Better

Same

Worse

Unknown

She/he did not have
that problem
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